DRTSW (DRTSW) Stock Price & Analysis
DRTSW (DRTSW) fell 9.92% to USD 3.18 as of July 26, 2026 at 11:03 UTC, according to Nexqual real-time market data.
DRTSW last closed at USD 3.53; the session ranged USD 3.15–3.62 on volume of 29,854 shares. Market capitalization is —, with a 52-week range of USD 3.15–3.62 (NCM). Source: Nexqual, July 26, 2026 at 11:03 UTC.
Key Statistics (as of July 26, 2026 at 11:03 UTC)
| Price | USD 3.18 |
|---|---|
| Change | ▼ 9.92% (down) |
| Previous Close | USD 3.53 |
| Open | USD 0.33 |
| Day Range | USD 3.15 – 3.62 |
| 52-Week Range | USD 3.15 – 3.62 |
| Volume | 29,854 shares |
| Market Cap | — |
| Exchange | NCM |
Analyst Ratings (DRTSW)
Wall Street analysts rate DRTSW "None", per Nexqual as of July 26, 2026 at 11:03 UTC.
| Consensus Rating | None |
|---|
Earnings (DRTSW)
| Revenue Estimate | $192,670 |
|---|
Source: Nexqual, July 26, 2026 at 11:03 UTC.
Financials & Fundamentals (DRTSW)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -90.51% |
| Debt / Equity | 20.68 |
| Current Ratio | 7.79 |
| Total Cash | $76.42M |
| Total Debt | $14.34M |
Source: Nexqual, July 26, 2026 at 11:03 UTC.
Financial Health Score (DRTSW)
Nexqual rates DRTSW's overall financial health "Mixed" across five dimensions, as of July 26, 2026 at 11:03 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $76M cash vs $14M debt, net cash position |
| Cash Flow | Mixed — No data |
| Efficiency | Critical — ROE -91%, ROA -30.5% |
Ownership (DRTSW)
| Float | 61.94M |
|---|
Source: Nexqual, July 26, 2026 at 11:03 UTC.
Leadership (DRTSW)
DRTSW is led by Uzi Sofer (age 55), CEO & Chairman, per Nexqual as of July 26, 2026 at 11:03 UTC.
| CEO & Chairman | Uzi Sofer (age 55) |
|---|---|
| Chief Financial Officer | Raphi Levy (age 40) |
| Chief Technology Officer | Ronen Segal (age 52) |
| Chief Scientific Officer & Member of Scientific Advisory board | Yona Keisari (age 78) |
| Vice President of legal | Rebecca Becker |
Major Backers & Investors (DRTSW)
Notable institutional backers of DRTSW include Aristeia Capital, LLC, MMCAP International, Inc. SPC, LMR Partners LLP, according to Nexqual as of July 26, 2026 at 11:03 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Aristeia Capital, LLC | 2.32% |
| MMCAP International, Inc. SPC | 1.91% |
| LMR Partners LLP | 1.75% |
| Moore Capital Management, LP | 0.75% |
| Value Base Ltd. | 0.65% |
| Tenor Capital Management Co., L.p. | 0.64% |
| Whitebox Advisors, LLC | 0.58% |
| Wolverine Asset Management, LLC | 0.55% |
Source: Nexqual, July 26, 2026 at 11:03 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DRTS | Alpha Tau Medical Ltd. | USD 12.5 | ▼ 3.92% |
| DRMAW | Dermata Therapeutics, Inc. Warrant | USD 0.01 | ▼ 4.81% |
| REVBW | Revelation Biosciences, Inc. | USD 0.01 | ▲ 1.01% |
| CINGW | Cingulate Inc. Warrants | USD 0.02 | ▼ 2.34% |
| CELUW | Celularity Inc. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 11:03 UTC. This page is informational and not investment advice.